Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023
24 Outubro 2023 - 5:05PM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the
“Company”), an eyecare technology company focused on developing and
commercializing innovative technology intended to transform care
and improve patients’ lives, today announced it will report
financial results for the third quarter ended September 30, 2023,
after the market close on Tuesday, November 7, 2023. The company’s
management will discuss the results during a conference call
beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the
conference call may do so by accessing a live and archived webcast
of the event at www.sightsciences.com, on the Investors page in the
News & Events section. The webcast will be available for replay
for at least 90 days after the event.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative solutions intended to transform care and
improve patients’ lives. Using minimally invasive or non-invasive
approaches to target the underlying causes of the world’s most
prevalent eye diseases, Sight Sciences seeks to create more
effective treatment paradigms that enhance patient care and
supplant conventional outdated approaches. The Company’s OMNI®
Surgical System is a minimally invasive glaucoma surgery (“MIGS”)
technology indicated to reduce intraocular pressure in adult
patients with primary open-angle glaucoma (“POAG”), the world’s
leading cause of irreversible blindness. The Company’s TearCare
System technology is 510(k) cleared for the application of
localized heat therapy in adult patients with evaporative dry eye
disease due to meibomian gland dysfunction (“MGD”) when used in
conjunction with manual expression of the meibomian glands,
enabling office-based clearance of gland obstructions by physicians
to address the leading cause of dry eye disease. The Company’s
SION™ Surgical Instrument is a manually operated device used in
ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit
www.sightsciences.com.
OMNI and TearCare are registered trademarks of
Sight Sciences.SION is a trademark of Sight Sciences.
© 2023 Sight Sciences. All rights reserved.
Media contact
pr@SightSciences.com
Investor contact:Philip
TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024